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Background and Aims: Obesity is associated with an increased risk of 2 
cardiovascular disease, but the mechanisms involved are not completely 3 
understood. In obesity, the adipocyte microenvironment is characterised by both 4 
hypoxia and inflammation. Therefore, we sought to determine whether extracellular 5 
vesicles (EVs) derived from adipocytes in this setting might be involved in mediating 6 
cardiovascular disease, specifically by promoting leukocyte attachment to vascular 7 
endothelial cells. 8 
Methods: Mature 3T3-L1 adipocytes were incubated for 24 hours under control, 9 
TNF-α (30 ng/mL), hypoxia (1% O2), or TNF-α+hypoxia (30 ng/mL, 1% O2) 10 
conditions. EVs were isolated by differential ultracentrifugation and analysed by 11 
nanoparticle tracking analysis. Primary human umbilical vein endothelial cells 12 
(HUVECs) were treated with EVs for 6 hours before being lysed for Western blotting 13 
to investigate changes in adhesion molecule production, or for use in leukocyte 14 
attachment assays. 15 
Results: EVs from adipocytes treated with TNF-α and TNF-α+hypoxia increased 16 
vascular cell adhesion molecule (VCAM-1) production in HUVECs compared to 17 
basal level (4.2 ± 0.6 and 3.8 ± 0.3-fold increase, respectively (p<0.05)), an effect 18 
that was inhibited by an anti-TNF-α neutralising antibody. Production of other 19 
adhesion molecules (E-selectin, P-selectin, platelet endothelial cell adhesion 20 
molecule and VE-Cadherin) were unchanged. Pre-incubating HUVECs with TNF-21 
α+hypoxia EVs significantly increased leukocyte attachment compared to basal level 22 
(3.0 ± 0.4-fold increase (p<0.05)). 23 
Conclusions: Inflammatory adipocyte EVs induce VCAM-1 production in vascular 24 
endothelial cells, accompanied by enhanced leukocyte attachment. Preventing 25 
adipocyte derived EV-induced VCAM-1 upregulation may offer a novel therapeutic 26 
target in the prevention of obesity-driven cardiovascular disease. 27 




Obesity is a risk factor for the development of cardiovascular disease (CVD)1 but the 2 
complex mechanisms linking the two together are still to be fully elucidated. Obesity 3 
combined with metabolic syndrome (an umbrella term encompassing insulin 4 
resistance, dyslipidaemia, vascular endothelial dysfunction, hypertension and a 5 
hypercoagulable state), further increases the risk of CVD2, 3.  Whilst a complete 6 
understanding of the mechanisms that trigger adipose tissue to become 7 
metabolically dysregulated in obesity are not fully understood, evidence suggests 8 
that hypoxia and inflammation play a role. 9 
Obese adipose tissue contains localised regions of hypoxia4-7 thought to arise due to 10 
increased cell number and cell size beyond the distance oxygen can diffuse from 11 
capillaries. Free fatty acids and cytokines produced by hypoxic adipocytes attract 12 
and activate macrophages and in doing so, induce local tissue inflammation8. Under 13 
such conditions, physiological adipokine production is dysregulated. For example, 14 
release of pro-inflammatory tumour necrosis factor (TNF)-α is increased9 whilst anti-15 
inflammatory adiponectin is decreased10. The elevation of TNF-α and decrease of 16 
adiponectin in plasma are individually associated with increased leukocyte 17 
attachment to vascular endothelial cells via increased production of vascular 18 
endothelial cell adhesion molecules11, 12. Subsequent phagocytosis of oxidised low-19 
density lipoproteins within vessel walls results in lipid-laden foam cell formation13 and 20 
later, atherosclerotic plaque development. 21 
Like most cells, adipocytes release extracellular vesicles (EVs)14, 15. EVs are 22 
membrane-bound structures that can convey biological information from a cell of 23 
origin to a recipient cell to achieve a target effect. Based on diameter and biogenesis 24 
they are categorised into three broad groupings: exosomes (~80-100 nm; released 25 
from multivesicular bodies upon plasma membrane fusion), microvesicles (~200-26 
1000 nm; shed directly from the plasma membrane) and apoptotic bodies (~1-5 µm; 27 
released as blebs during apoptosis). In vitro data show that adipocytes release EVs 28 
containing adipokines16-19. In obesity, adipocytes reside in a hypoxic and 29 
inflammatory environment, therefore the content and function of adipocyte-derived 30 
EVs in this environment may be different to adipocyte-derived EVs from lean adipose 31 
tissue. Adipocyte EVs circulating in obesity may contribute to vascular endothelial 32 
dysfunction which later leads to atherosclerotic plaque formation. We sought to test 33 
this hypothesis in vitro using a leukocyte attachment assay with vascular endothelial 34 
cells isolated from umbilical cords and EVs derived from adipocytes cultured in 35 
conditions representative of lean and obese (hypoxic and inflammatory) adipose 36 
tissue.  37 
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Materials and Methods 1 
Ethical approval for this study was granted by the NHS Health Research Authority 2 
(ethics committee reference: 14/NW/1459), and Cardiff Metropolitan University’s 3 
Research Ethics Committee.  4 
Adipocyte Culture and EV Isolation 5 
3T3-L1 adipocytes were cultured for 14 days as described by Connolly et al16. For all 6 
EV-isolation experiments, serum-containing culture medium was replaced with 7 
serum-free medium for 24 hours. During this time, adipocytes were exposed to one 8 
of four treatments representative of control (95 % air / 5 % CO2), inflamed (30 ng/mL 9 
TNF-α (13473019, ThermoFisher, USA)), hypoxic (1 % O2), and inflamed and 10 
hypoxic (30 ng/mL TNF-α, 1 % O2) adipose tissue. Cell media were centrifuged at 4 11 
°C at 1,000 g (5 minutes), 15,000 g (15 minutes), and finally 100,000 g (1 hour) to 12 
pellet EVs. EVs were resuspended in 1× PBS and quantified by nanoparticle tracking 13 
analysis (NTA; a technique that tracks nanoparticles in suspension using a laser, 14 
and based on Brownian motion, determines particle size and concentration). NTA 15 
was performed using a NanoSight LM10 with a 642 nm laser (Malvern Instruments 16 
Ltd, Malvern, UK), using software version 2.3, screen gain 4 and camera level 10. 17 
Five, one-minute videos were recorded per sample with analysis screen gain 10 and 18 
detection threshold 4. Temperature ranged from 20 to 23.5 °C. 19 
HUVEC Isolation and Culture 20 
Human umbilical cords were obtained following elective Caesarean sections. Saline 21 
was used to flush blood out of the umbilical vein, before one end was clamped. 22 
Collagenase type 1A (1 mg/mL; C5894, Sigma) in Medium 199 (M199; 31150, 23 
ThermoFisher) at 37 °C, was syringed into the vein until the cord became taut and 24 
then the end of the cord was also clamped. After 15 minutes, one clamp was 25 
released allowing the vascular endothelial cell suspension to be collected into a 26 
Falcon tube. Copious growth medium (M199 containing 10 % (v/v) foetal bovine 27 
serum (10500-064, ThermoFisher), human epidermal growth factor (1 ng/mL; 28 
13453029, ThermoFisher), hydrocortisone (1 µg/mL; H0888, Sigma), gentamycin (35 29 
µg/mL; G1272, Sigma) and amphotericin (0.5 µg/mL; A2942, Sigma)) was added to 30 
terminate the enzymatic digestion. Cells were centrifuged (300 g, 5 minutes, 4 °C), 31 
resuspended in growth medium, and plated in 96-well plates for leukocyte 32 
attachment assays or 6-well plates for protein assays. Plates were pre-coated with 1 33 
% (w/v) bovine skin gelatin (G9391, Sigma) in 1× PBS. HUVECs were given 2 hours 34 
to adhere, before the medium was aspirated and replaced. HUVECs reached 35 
confluency within 4-7 days, were never passaged, and were used for experiments 36 
within 7 days. 37 
Leukocyte Isolation 38 
Blood (10 mL) was obtained from healthy volunteers by venepuncture and 39 
transferred into a universal container (UC) containing Heparin (100 µL, 5,000 I.U/mL, 40 
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Wockhardt, India). Dextran (2.5 mL, 6 % (w/v), Sigma) dissolved in 1× balanced salt 1 
solution (BSS; 0.13 M NaCl, 2.6 mM KCl, 8.0 mM Na2HPO4, 1.83 mM KH2PO4, pH 2 
7.4) was added and mixed by a single inversion. Blood was transferred into a fresh 3 
UC and allowed to fractionate for 1 hour. The buffy coat layer (~1.5 mL) was 4 
transferred into a fresh UC. Cells were collected by centrifugation (300 g, 2 minutes, 5 
room temperature) and the pellet resuspended in sterile H2O to burst any 6 
contaminating erythrocyte membranes. After 10 seconds the UC was filled with BSS 7 
and the leukocytes were pelleted as above. The pellet was resuspended in Krebs-8 
BSA (0.1 % (w/v) bovine serum albumin (BSA) in 1× Krebs (1.2 M NaCl, 0.48 M KCl, 9 
0.12 M KH2PO4, 0.12 M MgSO4, 0.13 M CaCL2, 2.5 M HEPES, pH 7.4)) that had 10 
been passed through a 0.22 µm pore sterile-filter (Merck Millipore, USA) for 11 
sterilisation and remove possible contaminating serum extracellular vesicles.  Cells 12 
were incubated on ice, in darkness, with CellTraceTM (1:1000; C34851, Invitrogen). 13 
After 10 minutes, leukocytes were centrifuged, resuspended in Krebs-BSA and left to 14 
settle on ice for 30 minutes. Prior to the attachment assay, the leukocyte suspension 15 
was diluted 1:10 with Krebs-BSA pre-warmed to 37 °C.  16 
Leukocyte Attachment Assay 17 
Serum-free M199 (150 µL) containing 1.2 ± 0.4 ×1010 (Control), 2.5 ± 0.4 ×1010 18 
(TNF-α), 8.6 ± 0.8 ×1010 (Hypoxia) and 1.2 ± 0.3 ×1011 (TNF-α & Hypoxia) adipocyte 19 
EV/mL (mean ± SEM; N=3, n=9), was added to individual wells of a 96-well plate 20 
containing a confluent monolayer of HUVECs. Wells were also used to determine 21 
basal leukocyte attachment (no EVs; negative control) or 100 ng/mL TNF-α to 22 
increase HUVEC VCAM-1 production (no EVs; positive control). After 6 hours, EVs 23 
were removed with three Krebs washes before 150 µL of the fluorescently-labelled 24 
leukocyte suspension was added to all wells. Plates were incubated for 30 minutes 25 
before non-adherent cells were removed with three Krebs washes. Three images 26 
from around the centre of each well were captured using an inverted fluorescence 27 
microscope. The percentage of total image area covered by leukocytes was 28 
determined using Image J software (1.49v; National Institutes of Health, USA). 29 
Incubation timings were based on published protocols20. Three separate sets of 30 
adipocyte-derived EVs were used in this experiment and each set of EVs was tested 31 
on three HUVEC samples (N=3, n=9). 32 
Effect of Adipocyte EVs on HUVEC Adhesion Molecule Production 33 
Serum-free M199 (1.5 mL) containing 1.2 ± 0.4 ×1010 (Control), 2.5 ± 0.4 ×1010 34 
(TNF-α), 8.6 ± 0.8 ×1010 (Hypoxia) and 1.2 ± 0.3 ×1011 (TNF-α & Hypoxia) adipocyte 35 
EV/mL (mean ± SEM, N=3, n=3), was added to individual wells of a 6-well plate of 36 
HUVECs for 6 hours. Another well was used for the determination of basal protein 37 
production (no EVs; negative control). EVs were removed with three 1× PBS washes 38 
before HUVECs were lysed using radioimmunoprecipitation assay buffer (Invitrogen) 39 
containing protease inhibitors (Roche, Switzerland). Lysates were centrifuged 40 
(12,000 g, 10 minutes, 4 °C) and supernatants frozen until required. The protein 41 
concentration of each sample was determined using a NanoDrop spectrophotometer 42 
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and samples analysed by Western blotting. Lysates were mixed with sample buffer 1 
and reducing agent (Invitrogen) and heated (95 °C, 10 minutes). Ten µg of total 2 
protein from each sample was loaded onto 4-12 % Bis-Tris gels (NovexTM, 3 
ThermoFisher) and SDS-PAGE performed (180 V, 1 hour). Resolved proteins were 4 
transferred to polyvinylidene difluoride membranes (40 V, 75 minutes). Membranes 5 
were blocked using 5 % (w/v) non-fat dried milk in 1× Tris-buffered saline containing 6 
0.05 % Tween-20 (TBST) (1 hour). Primary antibodies directed at proteins of interest 7 
(vascular cell adhesion molecule (VCAM-1; ab134047), E-selectin (ab18981), P-8 
selectin (ab59738), platelet endothelial cell adhesion molecule (PECAM; ab28364), 9 
vascular endothelial (VE)-cadherin (ab33168), endothelial nitric oxide synthase 10 
(eNOS; ab76198) (all Abcam, Cambridge, UK)) were diluted 1:500 in blocking buffer 11 
and incubated with membranes overnight. Membranes were then incubated with 12 
horseradish peroxidase (HRP)-conjugated anti-rabbit IgG (1:1000; 10794347, 13 
ThermoFisher) (2 hours). Protein bands developed on enhanced chemiluminescence 14 
film (10607665, Fisher Scientific). Membranes were re-probed for β-actin (1:2000; 15 
4970S, Cell Signalling Technology (CST), Netherlands) to confirm equal loading. 16 
Band densitometry was performed using Image J. Three sets of adipocyte-derived 17 
EVs were used in this experiment with each set tested on one HUVEC sample (N=3, 18 
n=3). 19 
Effect of Adipocyte EVs on the Plasma Membrane Expression of HUVEC 20 
Adhesion Molecules 21 
HUVECs were treated with 3T3-L1 EVs from each condition (control, TNF-α, 22 
hypoxia, TNF-α+hypoxia) as described above, then washed twice and detached from 23 
the culture plate using 200 μL 1× PBS. HUVECs were collected by centrifugation 24 
(300 g, 5 minutes) and then re-suspended in ice-cold FACS Buffer (1% BSA (v/v) in 25 
1× PBS). Flow cytometry was used to assess the surface adhesion molecule profile 26 
of HUVECs. Antibodies used for flow cytometric analysis were obtained from 27 
Biolegend® (BioLegend, San Diego, CA, USA). They include; phycoerythrin (PE) 28 
anti-human CD144, allophycocyanin (APC) anti-human VCAM-1, Alexafluor 647 anti-29 
human PECAM-1, PE anti human E-Selectin, and PECy7 anti-human ICAM-1. Cells 30 
were incubated with antibodies for 30 minutes at 4 °C in darkness before being 31 
analysed on an FC500 MPL flow cytometer (Beckman Coulter equipped with 488 nm 32 
and 633 nm lasers) and data captured on MPX Cytometer List Mode Data 33 
Acquisition and Analysis Software (version 2.2). Acquisition was terminated upon 34 
recording 10,000 events, and cells gated based on their forward scatter and side 35 
scatter characteristics. Fluorescence minus one (FMO) stains were used to set the 36 
positive gates for each antibody (See supplemental information and supplementary 37 
Figure 3 for gating strategy).Three separate sets of adipocyte- derived EVs were 38 
used in this experiment and each set of EVs was tested on one individual HUVEC 39 
sample (N=3, n=3). Mean Fluorescence Intensity (MFI) was used to compare 40 




TNF-α Neutralisation Assay 1 
A TNF-α neutralising antibody was used to determine whether EVs derived from 2 
adipocytes treated with TNF-α, mediated VCAM-1 upregulation in HUVECs. To 3 
neutralise any pre-existing TNF-α, HUVECs and adipocyte-derived EVs were 4 
incubated separately in serum-free culture medium containing 0, 3, 10, 30, 100 or 5 
300 ng/mL TNF-α neutralising antibody. After 2 hours, HUVEC media were removed 6 
and the EV-containing media were added to the corresponding wells. After 6 hours, 7 
HUVECs were lysed and VCAM-1 levels assessed by Western blotting, as 8 
previously described. Four sets of adipocyte-derived EVs were used in this 9 
experiment with each set tested on one HUVEC sample (N=4, n=4).  10 
Analysis of 3T3-L1 Cell and EV Proteins 11 
Adipocyte cell and EV lysates were assessed by Western blotting as previously 12 
described. Ten µg of total protein was loaded per lane for cell lysates, and 5 µg of 13 
total protein for EV lysates. Primary antibodies directed at fatty acid binding protein-4 14 
(FABP4; 3544S, CST), adiponectin (2789S, CST), peroxisome proliferator-activated 15 
receptor gamma (PPARγ; 2443S, CST) and perilipin (9349S, Cell Signalling 16 
Technology), were used at a 1:500 dilution, and HRP-conjugated anti-rabbit IgG was 17 
used at a 1:1000 dilution. Three sets of adipocyte cell and EV lysates were used 18 
(N=3, n=3). 19 
Statistical Analyses 20 
Data are presented as mean or mode ± SEM. A one-way ANOVA with Tucky’s 21 
Multiple Comparison Test was used to analyse differences. Data were analysed 22 
using GraphPad Prism (version 6; GraphPad Software Inc., USA) and p-values 23 




Effect of Adipocyte EVs on Leukocyte-to-Endothelial Cell Attachment 2 
HUVECs pre-treated with TNFα+hypoxia-derived adipocyte EVs, increased 3 
leukocyte attachment to the same extent as the positive control (Figure 1A). These 4 
increases were significant when compared to those observed for HUVECs not 5 
treated with EVs and HUVECs pre-treated with control adipocyte EVs (Figure 1A). 6 
Leukocyte attachment was also greater following treatment with TNFα+hypoxia-7 
derived EVs compared to hypoxia-derived adipocyte EVs. Pre-treating HUVECs with 8 
TNF-α-derived adipocyte EVs also increased leukocyte attachment compared to 9 
HUVECs not treated with EVs. No other differences were observed in leukocyte 10 
attachment to HUVECs after pre-treatment with adipocyte EVs. Using size-exclusion 11 
chromatography, we confirm that TNF-α is associated with EVs; there is no free 12 
TNF-α (Supplementary Figure 1). 13 
Effect of Adipocyte EVs on HUVEC Protein Production  14 
Following treatment of HUVECs with adipocyte EVs, Western blotting was used to 15 
examine the production of proteins involved in leukocyte attachment (Figure 2). 16 
VCAM-1 production was increased in HUVECs treated with TNF-α EVs and TNF-17 
α+hypoxia EVs compared to that of untreated HUVECs. No change was observed 18 
with control EVs nor hypoxia EVs (Figure 2A). The production of other adhesion 19 
proteins including E-selectin (Figure 2B), P-selectin (Figure 2C) and PECAM (Figure 20 
2D) were unaffected by treatment with adipocyte EVs. In addition, no effect on the 21 
production levels of the vascular endothelial cell marker proteins VE-Cadherin 22 
(Figure 2E) and eNOS (Figure 2F) were identified.  23 
Effect of Adipocyte EVs on the Plasma Membrane Expression of HUVEC 24 
Adhesion Molecules 25 
Flow cytometry confirmed the expression of VCAM-1, E-selectin, PECAM-1 and 26 
ICAM-1 on HUVEC plasma membranes (Figure 3). However, there were no 27 
statistically significant differences in the mean fluorescence intensity for each protein 28 
between any of the treatment groups. TNF-α treatment (no EVs) of HUVECs was 29 
used as a positive control in all experiments and showed positive expression of 30 
adhesion markers, other than for PECAM-1 which showed high expression at 31 
baseline and following all treatment conditions.  32 
TNF-α Neutralisation Prevents VCAM-1 Upregulation in HUVEC 33 
To determine if the upregulation of VCAM-1 in HUVECs seen following treatment 34 
with TNF-α and TNF-α+hypoxia adipocyte EVs (Figure 2) is due to EV-associated 35 
TNF-α, a TNF-α neutralising antibody was used. Compared to untreated HUVECs, 36 
TNF-α+hypoxia EVs increased VCAM-1 production (Figure 4). Compared to the level 37 
of VCAM-1 production achieved following treatment with TNF-α+hypoxia EVs, co-38 
treatment with 100 ng/mL and 300 ng/mL neutralising antibody completely inhibited 39 
VCAM-1 upregulation (Figure 4). 40 
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Adipokine Production in Adipocytes and Adipocyte-Derived EVs  1 
No effect on the production of FABP4 in cell lysates due to any treatment was 2 
identified (Figure 5A). FABP4 in was increased in EVs lysates of cells treated with 3 
TNF-α regardless of normoxia or hypoxia (Figure 5B). Adiponectin production was 4 
decreased in cells treated with TNF-α+hypoxia compared to that of control cells, but 5 
individually, TNF-α and hypoxia had no effect (Figure 5C). All treatments appeared 6 
to decrease adiponectin in EV lysates compared to that of control cells (Figure 5D). 7 
PPARγ production in cell lysates decreased in response to hypoxia and TNF-8 
α+hypoxia (Figure 5E). Conversely, hypoxia- and TNF-α+hypoxia-derived EVs 9 
contained more PPARγ (Figure 5F). Compared to that of control cells, perilipin 10 
production decreased in response to hypoxia and TNF-α+hypoxia (Figure 5G). No 11 
differences in the production of perilipin in EVs were identified (Figure 5H). 12 
Effect of Inflammatory and Hypoxic Stimuli on Adipocyte EV Yield and Size. 13 
Compared to control adipocytes, treatment with TNF-α, hypoxia and TNF-α+hypoxia 14 
all increased the number of EVs produced per cell (Figure 6A). Treatment with TNF-15 
α, hypoxia, or TNF-α+hypoxia all decreased EV size compared to control adipocytes 16 




Increased adiposity has long been recognised as a risk factor for cardiovascular 2 
disease development1.  In obesity, adipose tissue inflammation is associated with 3 
vascular inflammation21 and one of the primary mediators of this process is the 4 
inflammatory cytokine, TNF-α. Whilst TNF-α is secreted by adipocytes themselves, 5 
levels in obese adipose tissue are predominantly raised by activated macrophages22. 6 
TNF-α desensitizes adipocytes to insulin23, but distally and in terms of effects on 7 
vascular endothelial cells, plasma TNF-α levels positively correlate with adhesion 8 
molecule production, disrupted eNOS activity and oxidative stress24. We are the first 9 
to show that EVs derived from adipocytes residing within a hypoxic and 10 
inflammatory, TNF-α-containing environment (modelling the pathophysiological 11 
inflammatory nature of obese adipose tissue in vivo), are implicated in the onset of 12 
vascular disease by increasing vascular endothelial cell adhesion molecule 13 
production and thereby promoting leukocyte attachment. In addition, we show that 14 
inflammatory and hypoxic stimuli affect the content of adipocyte-derived EVs, as well 15 
as their yield and size. 16 
Leukocyte-to-endothelial cell attachment was increased following treatment of 17 
HUVECs with TNF-α and TNF-α+hypoxia derived adipocyte EVs when compared to 18 
untreated HUVECs. However, when compared to the level of leukocyte attachment 19 
following treatment of HUVECs with control EVs, attachment was only increased 20 
following treatment with TNF-α+hypoxia EVs. This suggests that a factor(s) 21 
conferred by hypoxia, can elicit a functional effect on vascular endothelial cells that 22 
exacerbates leukocyte adhesion in the presence of inflammation, and this is worthy 23 
of future investigation. The data do however, indicate that inflammatory EVs, 24 
regardless of whether they were produced under normoxic or hypoxic conditions, 25 
prime endothelial cells for subsequent leukocyte attachment.  26 
Whilst flow cytometry confirmed the expression of the adhesion molecules VCAM-1, 27 
E-selectin, PECAM-1 and ICAM-1 on the surface of HUVEC plasma membranes, no 28 
differences between EV treatment groups were observed. Although not significant 29 
VCAM-1 surface expression did, however, show a trend to increase in cells treated 30 
with TNF-α and TNF-α+hypoxia derived adipocyte EVs and mirrored the increase in 31 
VCAM-1 detected by Western blotting. We hypothesize that in order to detect subtle 32 
changes in surface marker expression between treatment groups will likely require a 33 
very high number of HUVEC/experimental replicates and it is acknowledged further 34 
studies will be required in order to investigate differences in surface expression. 35 
The fact that inflammatory adipocyte EVs increase HUVEC VCAM-1 production, 36 
does however, offer a mechanism through which leukocyte-to-endothelial cell 37 
attachment is achieved. TNFR1 receptors have been shown to induce VCAM-1 38 
mRNA and protein via a pathway mediated by NF-κB but not ERK, p38MAPK or JNK 39 
kinase25. Future experiments aim to determine if the TNF-α delivered to HUVECs by 40 
11 
 
3T3-L1 EVs activates TNFR1 receptors and mediates VCAM-1 upregulation via a 1 
similar mechanism. As TNF-α neutralisation prevents VCAM-1 upregulation, we 2 
hypothesise that this would also prevent the increase in leukocyte-to-endothelial cell 3 
attachment following incubation of HUVEC with TNF-α and TNF-α+hypoxia derived 4 
adipocyte EVs. In vivo, VCAM-1 is involved in the firm attachment of leukocytes to 5 
endothelial cells prior to their transmigration though the vessel wall26, 27, and whilst 6 
enhanced VCAM-1 production accompanied by leukocyte attachment is known to 7 
contribute to the progression of atherosclerosis28, 29, we can now suggest that this is 8 
at least partly mediated by EVs derived from hypoxic and inflamed adipocytes.  9 
In this study, EVs were not processed further to remove possible contaminating 10 
“free” TNF-α. However, we do provide evidence that TNF- α co-elutes with CD63 11 
and FABP-4 following size exclusion chromatography of EV samples and that no 12 
“free” TNF-α elutes in later fractions. This indicates that TNF- α within EV samples is 13 
EV-associated (Supplementary Figure 1). In addition, it is important to note that the 14 
leukocytes for the leukocyte-to-endothelial attachment assay were isolated from 15 
heparin-anticoagulated blood. Heparin may activate platelets30 causing them to 16 
expose P-selectin. P-selectin can consequentially bind to P-selectin glycoprotein on 17 
leukocytes, and this may have affected leucocyte attachment31. However, this effect 18 
would be equal across all experimental conditions, and as such, the results observed 19 
in this study can be attributed to 3T3-L1 EVs. It is also important to note that once 20 
isolated from blood, the leukocytes were resuspended in 0.22 µm sterile-filtered 21 
Krebs-BSA. As such, there is a chance that bovine serum EVs smaller than 0.22 µm 22 
were present in this buffer and that they too could have affected leukocyte adhesion. 23 
Likewise, this effect would have been equal across all conditions and 24 
consequentially the levels of leukocyte attachment observed across all experimental 25 
conditions would remain in proportion to each other.  26 
Our results add to the growing body of literature confirming that adipocytes not only 27 
release EVs 15, 16, 32, but that the information conveyed through their content has a 28 
functional effect on other cell types. As such, we investigated the effect of 29 
inflammatory and hypoxic stimuli on the production of several proteins (FABP4, 30 
adiponectin, PPARɣ and perilipin) linked to cardiovascular disease in both adipocyte 31 
cell and EV lysates. We hypothesise that differences in the content of these proteins 32 
within EVs derived from inflammatory and/or hypoxic adipocytes may confer 33 
mechanistic influences on leukocyte attachment to vascular endothelial cells. Future 34 
studies will seek to identify and elucidate such mechanisms. 35 
Plasma levels of FABP4, a fatty-acid chaperone protein33, have been shown to 36 
increase in obesity34 and are associated with vascular endothelial cell dysfunction35. 37 
We observed no change in the FABP4 content of adipocyte cell lysates in response 38 
to inflammatory or hypoxic stimuli. This result supports a previous study whereby 39 
FABP4 production in adipocyte cell lysates was also shown not to change in 40 
response to hypoxia36. What is interesting, however, is that the authors of this study 41 
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did identify an increased level of FABP4 in adipocyte culture media in response to 1 
hypoxia. In our study, hypoxia did not increase the FABP4 content of EVs suggesting 2 
that perhaps FABP4 is released by adipocytes in an EV-independent mechanism in 3 
this setting. However, we did observe an increase in FABP4 in the lysates of EVs 4 
derived from TNF-α treated adipocytes (regardless of normoxia or hypoxia). As such, 5 
future experiments will aim to elucidate the influence of FABP4 within inflamed 6 
adipocyte-derived EVs on vascular endothelial dysfunction. 7 
Adiponectin is abundant within the circulation of healthy people and exerts regulatory 8 
insulin-sensitising and anti-inflammatory effects37,38. Plasma adiponectin levels 9 
negatively correlate with degree of obesity39 and therefore also correlate with 10 
increased obesity-related co-morbidities including insulin resistance, type II diabetes 11 
and cardiovascular disease40. We found that a combined inflammatory and hypoxic 12 
stimulus decreased adiponectin in adipocyte cell lysates. EV-associated adiponectin 13 
also appeared to decrease compared to control in response to all treatments, but 14 
particularly hypoxia. Using the same adipocyte cell model, Chen et al., showed that 15 
hypoxia prevents soluble adiponectin secretion40, complementing our finding. Our 16 
data add to this by suggesting that at least a proportion of this reduction in 17 
adiponectin secretion under hypoxic conditions is because it is not being packaged 18 
into EVs. Reduced adiponectin within adipocyte EVs may contribute to the decrease 19 
in plasma adiponectin during obesity and thereby may contribute to the development 20 
of cardiovascular disease. 21 
PPARɣ is a nuclear receptor regulating the transcription of genes central to fatty acid 22 
and energy metabolism41. We found that hypoxia decreased PPARɣ production in 23 
adipocyte cell lysates. Down-regulation of intracellular PPARɣ in response to hypoxia 24 
is well documented16, 42 and is mediated by inhibition of its transcription by hypoxia 25 
inducible factor-1 (HIF-1α). Interestingly, in our study we also observed a 26 
simultaneous increase of PPARɣ within the lysates of EVs derived from hypoxic 27 
adipocytes, confirming that adipocyte EVs are selectively packaged depending on 28 
environmental cues. We hypothesize that HIF-1α may also be implicated in the 29 
selective packaging of PPARɣ into EVs destined for release, as a further means to 30 
reduce intracellular PPARɣ levels. Overall, this finding highlights that EVs do not 31 
necessarily possess the same content as their cell-of-origin, but rather that their 32 
content reflects the cell-of-origin’s current state. 33 
Perilipin is a protein localised to the surface of lipid droplets and is involved in 34 
lipolysis43. In our study, hypoxia decreased perilipin production within adipocyte cell 35 
lysates when normalised to total protein. Wang et al.,44 previously showed no 36 
difference in total perilipin production per individual adipocyte sampled from lean and 37 
obese adipose tissue but when normalised to total protein or fat cell surface area, 38 
perilipin levels were also significantly lower in obese samples. We propose that 39 
hypoxia restricts perilipin production in adipose tissue in obesity in vivo. In addition, 40 
whilst perilipin levels are increased in the circulation in obese mice and humans15 41 
13 
 
this may be because it is released in to the circulation from adipocytes as a free 1 
protein rather than being associated with EVs. This hypothesis fits with our results as 2 
we identified no difference in the perilipin content of adipocyte EVs in response to 3 
inflammatory and hypoxic stimuli. 4 
In terms of specific EV character, our group has previously shown that EVs isolated 5 
from adipocytes express the vesicular proteins CD9, CD63, Alix, tumour 6 
susceptibility gene (TSG101)16, and now show that they also exhibit characteristic 7 
cup-shape morphology by electron microscopy (Supplementary Figure 1). Here we 8 
show the yield and size of adipocyte-derived EVs can be modulated independently 9 
by external stimuli. TNF-α, hypoxia and TNF-α+hypoxia increased the yield of 10 
EVs/cell whilst decreasing their size. These physical changes may themselves also 11 
confer distinct functional effects. However, it is important to note that the size data 12 
presented is based solely on raw NTA values; no refractive index45 nor mathematical 13 
modelling46 was applied. 14 
In summary, we provide evidence that adipocytes residing in a hypoxic and 15 
inflammatory environment produce EVs capable of inducing VCAM-1 production in 16 
vascular endothelial cells, and that this effect promotes leukocyte attachment. We 17 
also show that both inflammatory and hypoxic stimuli not only influence the 18 
adipokine content of adipocytes and their EVs, but also effect EV yield and size. 19 
Future studies will further explore the functional impact inflammatory and hypoxic 20 
adipocyte EVs have on cardiovascular disease. Indeed, the functional effects of 21 
adipocyte EVs in the setting of obesity, are likely to be not solely limited to vascular 22 
endothelial cells. We anticipate that a better understanding of the mechanisms 23 
though which adipocyte EVs negatively impact the vascular endothelium will open 24 
the door for the development of novel therapies for preventing and treating obesity-25 
driven cardiovascular disease.26 
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Figure Legends 21 
Figure 1 – Leukocyte attachment to HUVECs pre-treated with and without 22 
adipocyte-derived EVs. (A) Ratio of percentage area covered by leukocytes to a 23 
confluent monolayer of HUVECs pre-treated with (C) control, (T) TNF-α, (H) hypoxia, 24 
and (TH) TNF-α+hypoxia-derived adipocyte EVs relative to that of (B; Basal) 25 
HUVECs not treated with EVs (negative control). Direct treatment with TNF-α acted 26 
as a positive control (mean ± SEM; N=3, n=9; *** p<0.001). (B) Representative 27 
fluorescent images used to determine the percentage area of HUVECs covered by 28 
leukocytes. White dots are leukocytes stained with CellTrace
TM
. Scale bar = 200 µm. 29 
 30 
Figure 2 – Expression of adhesion and endothelial marker proteins in HUVECs 31 
following treatment with adipocyte EVs. Densitometry graphs and representative 32 
Western blots showing the ratio of (A) VCAM-1 (110 kDa), (B) E-Selectin (80 kDa), 33 
(C) P-Selectin (140 kDa), (D) PECAM (130 kDa), (E) VE-Cadherin (115 kDa) and (F) 34 
eNOS (140 kDa) expression in HUVECs following treatment with (C) control, (T) 35 
TNF-α, (H) hypoxia and (TH) TNF-α+hypoxia derived adipocyte EVs, relative to that 36 
of (B; basal) untreated HUVECs (mean ± SEM; N=3, n=3; *** p<0.001). β-actin 37 




Figure 3 - Surface expression of HUVEC adhesion proteins following treatment 2 
with adipocyte EVs. Mean fluorescence intensity graphs showing the ratio of (A) 3 
VCAM-1 (-APC), (B) E-Selectin (-PE), (C) PECAM-1 (-AlexoFluor) and (D) ICAM-1 (-4 
PE/Cy7) expressed on the plasma membrane of HUVECs following treatment with 5 
(C) control, (T) TNF-α, (H) hypoxia and (TH) TNF-α+hypoxia derived adipocyte EVs, 6 
relative to that of (B; basal) untreated HUVECs. Direct treatment with TNF-α was 7 
used as a positive control (mean ± SEM; N=3, n=3 for all except ICAM-1 where N=2, 8 
n=2). 9 
 10 
Figure 4 – TNF-α neutralisation inhibits endothelial VCAM upregulation 11 
following treatment with TNF-α+hypoxia adipocyte EVs. (A) Western blotting 12 
densitometry of VCAM-1 expression in control HUVEC lysates, and lysates of 13 
HUVECs treated with TNF-α+hypoxia EVs (denoted by +) in the presence of 0, 3, 10, 14 
30, 100 and 300 ng/ml TNF-α neutralising antibody (mean ± SEM; N = 4, n = 4; ** 15 
p<0.01). (B) Representative VCAM-1 (110 kDa; top) and β-actin (40 kDa; bottom) 16 
blots. Twenty µg total protein per lane. 17 
 18 
Figure 5. FABP4, adiponectin, PPARγ and perilipin expression in adipocyte and 19 
adipocyte-derived EV lysates. Densitometry graphs and representative Western 20 
blots for FABP4 and adiponectin in cell and EV lysates following (C) control, (T) TNF-21 
α, (H) hypoxia and (TH) TNF-α+hypoxia treatment of adipocytes. FABP4 expression 22 
in (A) cell lysates (mean ± SEM; N=6, n=6) and (B) EV lysates (mean ± SEM; N=4, 23 
n=4) (15 kDa). Adiponectin expression in (C) cell lysates (mean ± SEM; N=5, n=5; * 24 
p<0.05) and (D) EV lysates (mean ± SEM; N=2, n=2) (30 kDa). PPARγ expression in 25 
(E) cell lysates (mean ± SEM; N=6, n=6; *** p<0.001) and (F) EV lysates (mean ± 26 
SEM; N=3, n=3; ** p<0.01) (53 and 57 kDa). Perilipin expression in (G) cell lysates 27 
(mean ± SEM; N=5, n=5; *** p<0.001) and (H) EV lysates (mean ± SEM; N=3, n=3) 28 
(56 kDa). Twenty µg total protein per lane of cell lysates, and 5 µg total protein per 29 
lane of EV lysates. 30 
 31 
Figure 6. Effect of inflammatory and hypoxic stimuli on adipocyte EV yield and 32 
size. The effect of (C) control, (T) TNF-α, (H) hypoxia and (TH) TNF-α+hypoxia 33 
treatments on (A) EV yield per cell (mean ± SEM; n=3, n=9; *** p<0.001) and (B) EV 34 
size (mode ± SEM; n=3, n=9; *** p<0.001). 35 
 36 
  37 
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Figure 2 – Expression of adhesion and endothelial marker proteins in HUVECs 8 
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Figure 5. FABP4, adiponectin, PPARγ and perilipin expression in adipocyte and 2 
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